ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 164 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $35,752,000 | -88.2% | 425,160 | -87.4% | 0.01% | -88.7% |
Q3 2021 | $303,200,000 | -30.4% | 3,361,792 | -26.4% | 0.07% | -29.7% |
Q2 2021 | $435,636,000 | -48.1% | 4,568,805 | -38.0% | 0.10% | -50.7% |
Q1 2021 | $839,589,000 | -16.5% | 7,373,873 | +1.5% | 0.20% | -21.5% |
Q4 2020 | $1,005,265,000 | +80.3% | 7,261,901 | +7.0% | 0.26% | +56.3% |
Q3 2020 | $557,583,000 | +5.1% | 6,784,068 | +0.1% | 0.17% | -0.6% |
Q2 2020 | $530,298,000 | +81.6% | 6,779,565 | +3.1% | 0.17% | +46.1% |
Q1 2020 | $292,081,000 | +7.5% | 6,573,960 | +3.3% | 0.12% | +42.0% |
Q4 2019 | $271,751,000 | -0.1% | 6,362,695 | +0.1% | 0.08% | -9.0% |
Q3 2019 | $271,960,000 | -32.6% | 6,357,181 | +0.0% | 0.09% | -30.5% |
Q2 2019 | $403,678,000 | -8.4% | 6,357,126 | +0.0% | 0.13% | -8.6% |
Q1 2019 | $440,813,000 | +73.1% | 6,355,432 | +8.5% | 0.14% | +57.3% |
Q4 2018 | $254,626,000 | -43.0% | 5,856,155 | +0.0% | 0.09% | -31.5% |
Q3 2018 | $447,058,000 | +1.0% | 5,856,138 | +1.7% | 0.13% | +7.4% |
Q2 2018 | $442,430,000 | +46.7% | 5,755,563 | -2.7% | 0.12% | +40.7% |
Q1 2018 | $301,578,000 | +30.4% | 5,914,447 | +18.6% | 0.09% | +26.5% |
Q4 2017 | $231,205,000 | +6.1% | 4,985,005 | +21.9% | 0.07% | +3.0% |
Q3 2017 | $217,819,000 | -32.3% | 4,089,739 | -21.1% | 0.07% | -34.7% |
Q2 2017 | $321,937,000 | -7.1% | 5,183,330 | +1.4% | 0.10% | -7.3% |
Q1 2017 | $346,459,000 | -1.5% | 5,111,519 | +2.1% | 0.11% | -4.4% |
Q4 2016 | $351,892,000 | +2.7% | 5,004,859 | +3.6% | 0.11% | +0.9% |
Q3 2016 | $342,701,000 | +46.6% | 4,830,859 | +1.1% | 0.11% | +41.2% |
Q2 2016 | $233,700,000 | -22.6% | 4,778,169 | +0.2% | 0.08% | -23.1% |
Q1 2016 | $301,765,000 | -43.4% | 4,766,473 | +0.2% | 0.10% | -43.2% |
Q4 2015 | $533,581,000 | +16.9% | 4,756,473 | +0.4% | 0.18% | +12.3% |
Q3 2015 | $456,366,000 | +1.3% | 4,738,511 | +7.7% | 0.16% | +10.1% |
Q2 2015 | $450,318,000 | +69.6% | 4,398,068 | +2.9% | 0.15% | +62.6% |
Q1 2015 | $265,440,000 | +54.8% | 4,275,086 | +9.4% | 0.09% | +56.9% |
Q4 2014 | $171,465,000 | -20.8% | 3,907,586 | +2.1% | 0.06% | -22.7% |
Q3 2014 | $216,567,000 | +150.2% | 3,826,276 | +85.5% | 0.08% | +150.0% |
Q2 2014 | $86,566,000 | -3.7% | 2,063,176 | 0.0% | 0.03% | -6.2% |
Q1 2014 | $89,886,000 | – | 2,063,176 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |